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Background: Although breast cancer frequently metastasizes to the bones and brain, rarely breast cancer patients
may develop isolated liver metastasis. There is increasing data that anti-HER2 targeted therapy in conjunction with
systemic chemotherapy may lead to increased rates of pathologic complete response in the primary breast cancer.
However, little is known about its effects on metastatic liver disease.
Case presentation: We report the treatment of a 54-year-old female who was diagnosed with HER2-positive invasive
ductal carcinoma and synchronous breast cancer liver metastasis (BCLM). The patient underwent eight cycles of standard
docetaxel with two anti-HER2 targeted agents, trastuzumab and pertuzumab. Subsequent radiographic imaging
demonstrated complete radiographic response in the primary lesion with an approximate 75% decrease in the liver
metastasis. After informed consent the patient underwent modified radical mastectomy that revealed pathologic
complete response. Re-staging demonstrated no new disease outside the liver and a left hepatectomy was performed
for resection of BCLM. Final pathologic examination revealed no residual malignant cells in the liver specimen, indicating
pathologic complete response. Herein, we discuss the anti-HER2 targeted agents trastuzumab and pertuzumab and
review the data on dual HER2 antagonism for HER2-positive breast cancer and the role of surgical resection of BCLM.
Conclusions: The role of targeted agents for metastatic HER2-positive breast cancer is under active clinical trial
investigation and we await the maturation of trial results and long-term survival data. Our results suggest that these
agents may also be effective for producing considerable pathologic response in patients with BCLM.











Breast cancer is a major public health concern and af-
fects tens of thousands of women worldwide each year.
In approximately 25% of patients, the breast cancer cells
over-express human epidermal growth factor receptor-2
(HER2) on the cell surface, which results in a more aggres-
sive breast cancer phenotype and significantly decreased
overall and disease-specific survival compared with pa-
tients whose breast cancer does not overexpress HER2 [1].
Monoclonal antibodies, such as trastuzumab, that bind to
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article, unless otherwise stated.treat patients with HER2-overexpressing breast cancer with
metastases to organs outside of the breast. In this paper
we present a case of HER2-positive breast cancer liver me-
tastasis successfully treated with anti-HER2 targeted ther-
apy resulting in a complete pathologic response.
Case presentation
A 54-year-old Caucasian female with no past medical
history or co-morbidities presented to an outside institu-
tion with 3-month history of an enlarging palpable mass
in her left breast associated with skin thickening and
nipple retraction. The patient reported rapid growth of
the mass over the preceding month. Mammography was
ordered and revealed a 10 × 4 × 6 cm mass in the upper
outer quadrant of the left breast associated with pleo-
morphic calcifications (Figure 1). Ultrasound-guided biopsyCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public



















































Figure 2 Pre-treatment CT scan of the abdomen showing a
large hypodense mass in the left lobe of the liver (marked by
arrows); biopsy of the mass revealed metastatic HER2-positive
breast cancer.
Figure 1 Medial-lateral oblique mammogram of the left breast
demonstrating a large spiculated mass with calcifications in the
upper aspect of the breast (marked by arrows); biopsy of the mass
revealed HER2-overexpressing infiltrating ductal breast cancer.
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differentiated, grade 3 of 3, ER-negative, PR-negative,
HER2-positive infiltrating ductal carcinoma. Biopsy of an
enlarged 1.4 cm left axillary lymph node revealed meta-
static adenocarcinoma. Human epidermal growth factor
receptor-2 (HER2) protein expression was 3+ by immuno-
histochemistry and HER2 gene was amplified with a ratio
of 6.7 by fluorescence in situ hybridization; Ki-67 was
markedly elevated at 50%. High-grade comedo and solid
ductal carcinoma in situ (DCIS) was also identified. Meta-
static workup with computed tomographic scans of the
chest, abdomen, and pelvis revealed an 8.2 × 6.8 cm mass
in the left lobe of the liver (Figure 2), but no evidence of
metastatic disease elsewhere. The liver lesion was biopsied
and showed adenocarcinoma that was ER/PR-negative and
HER2-positive (Figure 3a and 3b), consistent with meta-
static breast cancer.Given the HER2-positive status, the patient was sched-
uled to receive chemotherapy in combination with HER2-
targeted monoclonal antibody trastuzumab, which binds
to HER2 and disrupts cell signaling and proliferation
[1]. Prior to the initiation of therapy, the US Food and
Drug Administration approved another anti-HER2 targeted
monoclonal antibody, pertuzumab, for first-line treatment
of HER2-positive metastatic breast cancer in combination
with docetaxel and trastuzumab. The approval was based
on results from the randomized Phase III Clinical Evalu-
ation of Pertuzumab and Trastuzumab (CLEOPATRA) trial
which showed increased progression-free survival (PFS) in
HER2-positive metastatic breast cancer patients treated
with docetaxel, trastuzumab, and pertuzumab compared to
docetaxel and trastuzumab alone.
The patient underwent eight cycles of docetaxel (75 mg/
m2 every three weeks), trastuzumab (8 mg/kg loading dose
on Day 2 of the first cycle followed by 6 mg/kg every three
weeks thereafter), and pertuzumab (840 mg loading dose
on Day 2 of the first cycle followed by 420 mg every three
weeks thereafter) over a total period of six months. The
patient tolerated therapy without adverse effects and
underwent re-staging with PET/CT after the 4th cycle
of treatment, demonstrating near 75% reduction in the
breast lesion. Additionally, the liver metastasis decreased
in size from 8 cm to 5 cm. Re-staging imaging studies
after the 8th cycle of therapy showed radiographic reso-
lution of the left breast mass and interval decrease of the
liver mass to 2 cm.
Since retrospective studies have suggested improved
survival for patients with stage IV breast cancer with re-
section of the primary tumor [2,3] and given the patient’s




















































Figure 4 CT scan of the abdomen showing a dramatic decrease
in size of the metastasis (marked by arrows) in the left lobe of
the liver after treatment with eight cycles of pertuzumab,
trastuzumab, and docetaxel.
Figure 3 PhotomicrographsQ1 of the primary left breast infiltrating
ductal carcinoma. Figure 3a demonstrates carcinoma cells (marked
with arrows) stained with hematoxylin and eosin (200X magnification).
Figure 3b demonstrates intense 3+ breast cancer cell surface staining
on immunohistochemistry indicating HER2 overexpression
(400X magnification).
Schoellhammer et al. BMC Cancer 2014, 14:242 Page 3 of 6
http://www.biomedcentral.com/1471-2407/14/242to resection of the primary breast cancer following the 8th
treatment cycle. As such, the patient underwent left modi-
fied radical mastectomy with tissue-expander reconstruc-
tion seven months after the diagnosis of stage IV breast
cancer was made. Final pathologic examination revealed
residual high-grade DCIS with necrosis (2.7 cm); however
no residual invasive carcinoma was identified. Therefore,
pathologic complete response (i.e., ypTisN0M1) of the
invasive tumor was observed. Due to the original size of
the primary lesion, the patient received standard post-
mastectomy radiation therapy to the left chest wall and
nodal basin. After the breast operation the patient was
continued on trastuzumab 6 mg/kg and pertuzumab
420 mg given every three weeks.
The patient subsequently transferred her care to our
institution and was evaluated for resection of the liver
metastasis. Triple-phase CT scan at our institution taken
12 months after her initial presentation revealed the lefthepatic lobe metastasis to be 2.3 × 2 cm without evidence
of metastatic disease elsewhere (Figure 4). The liver lesion
was deemed to be resectable and the patient underwent
left hepatectomy approximately five months after modi-
fied radical mastectomy had been performed. The patient’s
post-operative course was uncomplicated and she was
subsequently discharged home in excellent condition.
Final pathologic examination of the resected specimen re-
vealed an area of scar tissue with stromal hyalinization,
scattered histiocytes, and lymphocytic infiltrate measuring
1.2 cm. No residual malignant cells were identified in the
resected liver, thus indicating a complete pathologic re-
sponse (Figure 5). On surveillance imaging approximately
three months after resection, repeat CT of the abdomen/
pelvis demonstrated no evidence of new or recurrent dis-
ease in the liver (Figure 6). The patient continues to do
well without disease approximately 6 months after liver
surgery. Currently the optimal duration of anti-HER2
therapy for patients with long-term disease control is not
known [4], and as such the patient will remain on dual
agent pertuzumab and trastuzumab given every three weeks
indefinitely.Discussion
Breast cancer is the most common cancer in women
worldwide, accounting for 1.3 million new cases in 2008
(23% of all new cases) [5]. Ten to 15% of patients have
metastatic disease at the time of initial presentation [6],
and the most common sites of metastases are the bones
and brain with only 1-5% of breast cancer patients de-
veloping isolated liver metastasis [7,8]. Aggressive tumor
biology and corresponding poorer prognosis is associated
with amplification or overexpression of HER2, a trans-















































Figure 5 Photomicrograph of the left hepatectomy specimen
stained with hematoxylin and eosin, demonstrating normal
liver parenchyma marked with arrows, fibrotic tissue with
hyalinization and scattered lymphocytic infiltrate (marked by
arrowheads) without evidence of breast cancer cells, consistent
with response to treatment and indicating complete pathologic
response (40X magnification).
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teins [9]. Historically, patients with HER2-positive breast
cancer have had poor prognosis, with response rates to
chemotherapy ranging from 17-42% [1]. Now with the ad-
vent of anti-HER2 therapy, tumor response and patient
survival have dramatically improved [10,11].
The first anti-HER2 targeted agent was the monoclonal
antibody trastuzumab, which initially was approved for
the treatment of HER2-overexpressing breast cancer with
standard chemotherapy in the metastatic setting. Trastu-
zumab inhibits ligand-independent HER2 activity and re-




















Figure 6 CT scan of the abdomen performed three months
after resection of the left lobe of the liver demonstrating
normal-appearing right lobe of the liver without evidence of
new or recurrent metastatic disease.domain [12,13]; however trastuzumab binding does not
interfere with HER2 heterodimerization, which mediates
downstream cell proliferation [14]. Pertuzumab, the sec-
ond commercially approved selective anti-HER2 agent,
may act in synergy with trastuzumab to antagonize HER2
signaling by blocking HER2 heterodimerization and acti-
vating antibody-dependent cell-mediated cytotoxicity [15].
Treatment of HER2-positive breast cancer patients with
dual anti-HER2 antagonism translates to better thera-
peutic responses. In the CLEOPATRA trial approximately
80% of patients randomized to the experimental treatment
(docetaxel, trastuzumab, and pertuzumab) had an object-
ive tumor response compared to 69.3% with control treat-
ment (docetaxel and trastuzumab) [13]. In a Phase II trial
by Baselga et al., patients with metastatic HER2-positive
breast cancer received trastuzumab with pertuzumab and
had response rates of 24.2%, and 7.6% of patients had a
pathologic complete response [16]. In another Phase II
trial, the Neoadjuvant Study of Pertuzumab and Herceptin
in an Early Regimen Evaluation (NeoSphere) Trial, the
highest rates of pathologic complete response were ob-
served in patients receiving docetaxel, trastuzumab, and
pertuzumab. Interestingly, in patients receiving targeted
therapy alone (i.e., trastuzumab and pertuzumab) approxi-
mately 17% of patients had pathologic complete response,
demonstrating that dual HER2 inhibition alone may elicit
remarkable responses in HER2-positive breast cancers
[17]. Unfortunately, none of the aforementioned trials spe-
cifically characterize metastatic liver disease and it is un-
clear whether such results could reasonably be applied to
any metastatic site.
Our experience indicates that HER2-overexpressing
BCLM can be effectively treated with chemotherapy and
dual HER2 targeted therapy. This is important for pa-
tients with isolated liver metastases (1-5% of all meta-
static patients), because control and possibly cure of the
disease can be achieved. Indeed, liver resection has become
a treatment option for selected patients with BCLM. Prior
to the modern era, older studies showed no survival advan-
tage for metastatic breast cancer patients who underwent
liver resection, with five-year survival of 9% seen [18-20].
Now, contemporary studies routinely report survival ad-
vantages in select patients undergoing liver resection for
BLCM. Five-year overall survival rates approaching 21%-
38% are the norm with a combination of chemotherapy
and resection, and a wide variety of chemotherapeutic reg-
imens have been reported to be used in the literature,
commonly Adriamycin/cyclophosphamide or cyclophos-
phamide/methotrexate/fluorouracil [7,8,21]. The survival
rate of breast cancer patients with isolated liver metastasis
who have undergone liver resection has dramatically in-
creased due to medical advances and multidisciplinary
care: improved chemotherapy and targeted agents, more
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http://www.biomedcentral.com/1471-2407/14/242patients with HER2-positive BCLM, we expect that out-
comes in the future will be even further improved given
the high rates of tumor response to HER2 targeted ther-
apy and the possibility of achieving a complete pathologic
response.
Conclusion
The role of HER2 targeted agents such as pertuzumab will
continue to evolve in the treatment of patients with
BCLM, and may lead to curative therapeutic plans. There
is no data on pathologic complete response from this new
treatment option and we anticipate that our experience
may prove in the future to be a common and frequent
outcome. Targeted agents in combination with chemo-
therapy will undoubtedly increase the resectability of liver
metastasis. Continued multi-disciplinary treatment strat-
egies will be essential in the future to coordinate the roles
of targeted therapy and liver resection, ultimately with the
goal of providing patients improved survival benefit.
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